Drug intelligence / Profile preview

ActiveMatrix

Development stage: Phase 4
Lead developer: Skye Biologics
Administration: Surgical Implant, Topical

Overview

ActiveMatrix is a drug product investigated in a Phase 4 randomized controlled trial for reducing spinal surgical site infections (SSI), particularly in patients with lumbar spinal stenosis. The trial was sponsored by Baylor College of Medicine and Skye Biologics. The mechanism of action, active ingredient, and modality are not specified in the available sources.

Targets

MMP12 (Macrophage Metalloelastase)

Beyond the preview

Go deeper on ActiveMatrix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActiveMatrix.

Explore the full profile